×
About 50,416 results

ALLMedicine™ Renal Cell Carcinoma Center

Research & Reviews  23,929 results

Paraneoplastic Cone Dysfunction Secondary to Renal Cell Carcinoma: A Case Report.
https://doi.org/10.1097/WNO.0000000000001250
Journal of Neuro-ophthalmology : the Official Journal of ... Ghosh A, Bindiganavile SH et. al.

Apr 12th, 2021 - Paraneoplastic Cone Dysfunction Secondary to Renal Cell Carcinoma: A Case Report.|2021|Ghosh A,Bindiganavile SH,Bhat N,Lee AG,|

Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.
https://doi.org/10.1016/j.clgc.2021.03.003
Clinical Genitourinary Cancer; Santos VE, da Costa WH et. al.

Apr 11th, 2021 - To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC). A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed ...

Development of a four-gene prognostic model for clear cell renal cell carcinoma based o...
https://doi.org/10.1016/j.ygeno.2021.04.005
Genomics Liu Y, Huang Z et. al.

Apr 10th, 2021 - This study aimed to develop a prognostic model for clear cell renal cell carcinoma (ccRCC) based on transcriptome analysis. We screened Gene Expression Omnibus (GEO) database and the Cancer Genome Atlas (TCGA) database for gene expression data and...

RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of...
https://doi.org/10.1007/s00262-021-02913-8 10.1177/1724600818817557 10.1177/0391560318818951 10.2147/IJN.S215883 10.3389/fonc.2019.01033 10.1016/j.urolonc.2017.08.011 10.1016/j.clgc.2019.07.021 10.1371/journal.pone.0011404 10.1002/ijc.24466 10.1371/journal.pone.0015737 10.1074/jbc.M111.264192 10.1080/15548627.2015.1067362 10.1002/hed.21797 10.1371/journal.pone.0019629 10.2147/OTT.S169531 10.1002/cbin.11209 10.3892/ol.2018.9412 10.18632/oncotarget.4257 10.1038/bjc.2013.439 10.3892/or.2015.4269 10.1038/s41419-018-1005-z 10.1074/jbc.M116.769182 10.1002/jcp.28287 10.1016/j.celrep.2019.07.107 10.1038/nrurol.2011.43 10.1002/cam4.2542 10.1177/1756287219868859 10.1016/j.neo.2017.05.002 10.1093/nar/gnj004 10.1091/mbc.5.8.877 10.1016/j.yexcr.2019.06.011 10.1186/s13046-015-0180-3 10.3389/fonc.2019.00663 10.1016/j.biopha.2019.109578 10.1158/1078-0432.CCR-13-1588 10.1016/j.jdiacomp.2017.06.009 10.1093/carcin/bgw010 10.4161/cbt.8.9.8246 10.1083/jcb.149.2.423 10.1186/s13046-019-1221-0 10.1371/journal.pone.0131059 10.1245/s10434-012-2372-9 10.1128/MCB.00392-12 10.1158/0008-5472.CAN-17-3139 10.31557/APJCP.2019.20.10.2951 10.1186/s40425-019-0770-2 10.1080/17843286.2016.1260890 10.1111/cas.13099
Cancer Immunology, Immunotherapy : CII; Chen P, Duan Y et. al.

Apr 10th, 2021 - Rb1-inducible coiled-coil 1 (RB1CC1) has been demonstrated to function as an inhibitor of proline-rich/Ca-activated tyrosine kinase 2 (PYK2) by binding to the kinase domain of PYK2, which promotes the proliferation, invasion, and migration of rena...

see more →

Guidelines  97 results

Genetics of Renal Cell Carcinoma (PDQ®)–Health Professional Version
https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics
National Cancer Institute;

Mar 10th, 2021 - Renal cell carcinoma (RCC) is among the more commonly diagnosed cancers in both men and women. In the United States in 2021, about 76,080 cases of kidney cancer and renal pelvis cancer are expected to occur and lead to an estimated 13,780 deaths. ...

Renal Clear Cell Cancer - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK563230/
StatPearls [Internet]; Arora RD

Oct 15th, 2020 - Renal cell carcinoma, of which clear cell carcinoma is the most common histological subtype (80 to 90 percent), comprises 90 percent of all Kidney tumors.

Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
https://www.sciencedirect.com/science/article/pii/S2588931120300547
European Urology Oncology; Roussel E

Aug 30th, 2020 - Cytoreductive nephrectomy (CN) plays an important role in the treatment of a subgroup of metastatic renal cell carcinoma (mRCC) patients.

Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
https://ascopost.com/videos/asco20-virtual-scientific-program/eric-jonasch-on-a-novel-therapy-for-von-hippel-lindau-disease-associated-rcc/

May 31st, 2020 - Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated cle...

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 30th, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy rega...

see more →

Drugs  61 results see all →

Clinicaltrials.gov  25,223 results

Paraneoplastic Cone Dysfunction Secondary to Renal Cell Carcinoma: A Case Report.
https://doi.org/10.1097/WNO.0000000000001250
Journal of Neuro-ophthalmology : the Official Journal of ... Ghosh A, Bindiganavile SH et. al.

Apr 12th, 2021 - Paraneoplastic Cone Dysfunction Secondary to Renal Cell Carcinoma: A Case Report.|2021|Ghosh A,Bindiganavile SH,Bhat N,Lee AG,|

Prognostic Impact of Loss of SETD2 in Clear Cell Renal Cell Carcinoma.
https://doi.org/10.1016/j.clgc.2021.03.003
Clinical Genitourinary Cancer; Santos VE, da Costa WH et. al.

Apr 11th, 2021 - To evaluate the prognostic impact of immunohistochemical expression of SETD2 in patients with clear cell renal cell carcinoma (ccRCC). A total of 662 patients with primary or metastatic ccRCC were evaluated. Two genitourinary pathologist reviewed ...

Development of a four-gene prognostic model for clear cell renal cell carcinoma based o...
https://doi.org/10.1016/j.ygeno.2021.04.005
Genomics Liu Y, Huang Z et. al.

Apr 10th, 2021 - This study aimed to develop a prognostic model for clear cell renal cell carcinoma (ccRCC) based on transcriptome analysis. We screened Gene Expression Omnibus (GEO) database and the Cancer Genome Atlas (TCGA) database for gene expression data and...

RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of...
https://doi.org/10.1007/s00262-021-02913-8 10.1177/1724600818817557 10.1177/0391560318818951 10.2147/IJN.S215883 10.3389/fonc.2019.01033 10.1016/j.urolonc.2017.08.011 10.1016/j.clgc.2019.07.021 10.1371/journal.pone.0011404 10.1002/ijc.24466 10.1371/journal.pone.0015737 10.1074/jbc.M111.264192 10.1080/15548627.2015.1067362 10.1002/hed.21797 10.1371/journal.pone.0019629 10.2147/OTT.S169531 10.1002/cbin.11209 10.3892/ol.2018.9412 10.18632/oncotarget.4257 10.1038/bjc.2013.439 10.3892/or.2015.4269 10.1038/s41419-018-1005-z 10.1074/jbc.M116.769182 10.1002/jcp.28287 10.1016/j.celrep.2019.07.107 10.1038/nrurol.2011.43 10.1002/cam4.2542 10.1177/1756287219868859 10.1016/j.neo.2017.05.002 10.1093/nar/gnj004 10.1091/mbc.5.8.877 10.1016/j.yexcr.2019.06.011 10.1186/s13046-015-0180-3 10.3389/fonc.2019.00663 10.1016/j.biopha.2019.109578 10.1158/1078-0432.CCR-13-1588 10.1016/j.jdiacomp.2017.06.009 10.1093/carcin/bgw010 10.4161/cbt.8.9.8246 10.1083/jcb.149.2.423 10.1186/s13046-019-1221-0 10.1371/journal.pone.0131059 10.1245/s10434-012-2372-9 10.1128/MCB.00392-12 10.1158/0008-5472.CAN-17-3139 10.31557/APJCP.2019.20.10.2951 10.1186/s40425-019-0770-2 10.1080/17843286.2016.1260890 10.1111/cas.13099
Cancer Immunology, Immunotherapy : CII; Chen P, Duan Y et. al.

Apr 10th, 2021 - Rb1-inducible coiled-coil 1 (RB1CC1) has been demonstrated to function as an inhibitor of proline-rich/Ca-activated tyrosine kinase 2 (PYK2) by binding to the kinase domain of PYK2, which promotes the proliferation, invasion, and migration of rena...

see more →

News  1,101 results

High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC
https://www.medscape.com/viewarticle/947392

Mar 14th, 2021 - NEW YORK (Reuters Health) - In patients with metastatic renal cell carcinoma (mRCC) treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs), higher body mass index was associated with improved overall survival in a database study. "These...

Genetics of Renal Cell Carcinoma (PDQ®)–Health Professional Version
https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics
National Cancer Institute;

Mar 10th, 2021 - Renal cell carcinoma (RCC) is among the more commonly diagnosed cancers in both men and women. In the United States in 2021, about 76,080 cases of kidney cancer and renal pelvis cancer are expected to occur and lead to an estimated 13,780 deaths. ...

Combo Shows 'Impressive' Survival Results in First-Line RCC
https://www.medscape.com/viewarticle/946025

Feb 17th, 2021 - The combination of lenvatinib and pembrolizumab outperforms sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC), based on findings of the CLEAR trial. Results from the phase 3 trial were reported at the 2021 Genitour...

Cabozantinib Could Be New Standard for Papillary RCC
https://www.medscape.com/viewarticle/945955

Feb 16th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Compared with the VEGFR-2 inhibitor sunitinib, the MET ...

Which Patients With Kidney Cancer Are Likely to Respond to ICI?
https://www.medscape.com/viewarticle/945382

Feb 4th, 2021 - Several factors associated with a diminished response to immune checkpoint inhibitor (ICI) drugs among patients with metastatic clear cell renal cell carcinoma (ccRCC) have been identified. They include the patient being aged 75 years or older, be...

see more →

Patient Education  5 results see all →